For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Intellia Therapeutics and CRISPR/Cas9 Technology
Intellia Therapeutics (NTLA) is a genome editing company, focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment and creating enhanced . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.